News Ipsen's Cabometyx recommended by NICE for previously treated... French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care
News Disappointment for BMS as Zeposia fails Crohn’s study Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.